Prostate Cancer Clinical Trials in Dallas

Showing 201-220 of 275 trials

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

NCT01823978

This is a Phase I, non-randomized, dose escalation study of the safety, biomarkers, and preliminary efficacy of dendritic cell vaccine, BPX-201, plus activating agent, AP1903, in patients with metastatic castrate resistant prostate cancer.

Castrate Resistent Prostate Cancer

Bellicum Pharmaceuticals19 participantsStarted Apr 2013

Birmingham, Alabama, United States • Dallas, Texas, United States

TERMINATED< 1 mile

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

NCT01981109

The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.

Castration-Resistant Prostate Cancer

Dendreon225 participantsStarted Jan 2012

Anchorage, Alaska, United States • Tucson, Arizona, United States • Atherton, California, United States +55 more locations

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

Prostate Cancer Trials in Other Cities

Multi-Institutional Registry for Prostate Cancer Radiosurgery

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Vidaza to Restore Hormone Thx Prostate

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy

A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer

ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Other Conditions in Dallas